![](https://www.notionless.net/wp-content/uploads/2024/03/qmk3w-300x300.png)
As sales of appetite-suppressing drugs such as Ozempic and Mounjaro skyrocket, Corporate America is grappling with the question: How does a less-hungry, less-impulse-prone consumer affect my business model?
Companies from Walmart Inc. to Conagra Brands Inc. are weighing how much to factor the diabetes drugs known as GLP-1s, increasingly being used for weight loss, into t…
Read more